European Journal of Cancer
Volume 41, Issue 13 , Pages 1833-1841 , September 2005

Chemoprevention: From research to clinical oncology

  • Umberto Veronesi

      Affiliations

    • European Institute of Oncology, Via G. Ripamonti, 435, 20141 Milan, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 02 57489221/27; fax: +39 02 57489210.
    • ,
  • Bernardo Bonanni

      Affiliations

    • Division of Chemoprevention, European Institute of Oncology, Milan, Italy

Received 13 May 2005 ,Revised 20 May 2005 ,Accepted 20 May 2005.

References 

  1. Lippman SM, Levin B. Cancer prevention: strong science and real medicine. J Clin Oncol. 2005;23:249–253
  2. Lippman SM, Lee JJ, Sabichi AL. Cancer chemoprevention: progress and promise. J Natl Cancer Inst. 1998;90(20):1514–1528
  3. O’Shaughnessy JA, Kelloff GJ, Gordon GB, et al. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res. 2002;8:314–346
  4. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumour development. N Engl J Med. 1988;319:525–532
  5. Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. Science. 1997;278:1073–1077
  6. Braakhuis BJM, Tabor MP, Kummer JA, et al. A genetic explanation of slaughter’s concept of field cancerization. Cancer Res. 2003;63:1727–1730
  7. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353:1993–2000
  8. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998;90:1371–1388
  9. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215–224
  10. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342:1946–1952
  11. Baron JA, Beach M, Mandel JS, et al. Calcium supplements for the prevention of colorectal adenomas. N Engl J Med. 1999;340:101–107
  12. Baron JA, Cole BF, Sandler RS, et al. A randomised trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348:891–899
  13. Kelloff GJ, Sigman CC, Johnson KM, et al. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2000;9:127–137
  14. Decensi A, Robertson C, Viale G, et al. A randomised trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst. 2003;95:779–790
  15. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit. A new look at old data. Circulation. 1995;91:2274–2282
  16. Shi R, Yu H, McLarty J, Glass J. IGF-I and breast cancer: a meta-analysis. Int J Cancer. 2004;111(3):418–423
  17. Wedren S, Lovmar L, Humphreys K, et al. Oestrogen receptor alpha gene haplotype and postmenopausal breast cancer risk: a case control study. Breast Cancer Res. 2004;6:R437–R449
  18. Dooley WC, Ljung BM, Veronesi U, et al. Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst. 2001;93:1624–1632
  19. Boyd NF, Fishell E, Jong R, et al. Mammographic densities as a criterion for entry to a clinical trial of breast cancer prevention. Br J Cancer. 1995;72:476–479
  20. Johnston CC, Bjarnason NH, Cohen FJ, et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomised, placebo-controlled trials. Arch Intern Med. 2000;160:3444–3450
  21. Meyskens FL, Surwit E, Moon TE, Childers JM, et al. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomised trial. J Natl Cancer Inst. 1994;86:539–543
  22. Mitchell MF, Hittelman WN, Hong WK, et al. The natural history of cervical intraepithelial neoplasia: an argument for intermediate endpoint biomarkers. Cancer Epidemiol Biomarkers Prev. 1994;3:619–626
  23. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117–1130
  24. Pharoah PD, Antoniou A, Bobrow M, et al. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet. 2002;31:33–36
  25. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361:296–300
  26. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet. 1998;352:93–97
  27. Veronesi U, Maisonneuve P, Sacchini V, et al. Italian Tamoxifen Study Group Tamoxifen for breast cancer among hysterectomised women. Lancet. 2002;359:1122–1124
  28. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 1998;352:98–101
  29. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 2002;360:817–824
  30. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomised trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999;281:2189–2197
  31. Decensi A, Bonanni B, Guerrieri-Gonzaga A, et al. Biologic activity of tamoxifen at low doses in healthy women. J Natl Cancer Inst. 1998;90:1461–1467
  32. Veronesi U, Maisonneuve P, Rotmensz N, et al. Italian randomised trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst. 2003;95:160–165
  33. Decensi A, Robertson C, Rotmensz N, et al. Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial. Italian Chemoprevention Group. Br J Cancer. 1998;78:572–578
  34. Chang J, Powles TJ, Ashley SE, et al. The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study. Ann Oncol. 1996;7:671–675
  35. Bonanni B, Serrano D, Cazzaniga M, et al. A biomarker trial of low-dose tamoxifen in HRT users. Proc Front Cancer Prev Res. 2004;69;[abstr A2]
  36. Veronesi U, De Palo G, Marubini E, et al. Randomised trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst. 1999;91:1847–1856
  37. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365:60–62
  38. Goss PE, Ingle JN, Martino S, et al. A randomised trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793–1802
  39. Coombes RC, Hall E, Gibson LJ, et al. A randomised trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081–1092
  40. The Big 1-98 Collaborative Group. Primary therapy of early breast cancer conference, St Gallen, Switzerland, 2005 [abstr 54].
  41. Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med. 1992;326:658–662
  42. Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348:1467–1471
  43. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348(9040):1472–1477
  44. Vernon SW. Participation in colorectal cancer screening: a review. J Natl Cancer Inst. 1997;89:1406–1422
  45. Garcia Rodriguez LA, Varas C, Patrono C. Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology. 2000;11(4):382–387
  46. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002;94:252–266
  47. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993;328(18):1313–1316
  48. Schatzkin A, Lanza E, Corle D, et al. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med. 2000;342:1149–1155
  49. MacLennan R, Macrae F, Bain C, et al. Randomised trial of intake of fat, fiber, and beta carotene to prevent colorectal adenomas. J Natl Cancer Inst. 1995;87(23):1760–1766
  50. DeCosse JJ, Miller HH, Lesser ML. Effect of wheat fiber and vitamins C and E on rectal polyps in patients with familial adenomatous polyposis. J Natl Cancer Inst. 1989;81(17):1290–1297
  51. Bonithon-Kopp C, Kronborg O, Giacosa A, et al. Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial. European Cancer Prevention Organisation Study Group. Lancet. 2000;356(9238):1300–1306
  52. Clark LC, Combs Jr GF, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomised controlled trial. Nutritional Prevention of Cancer Study Group. JAMA. 1996;276(24):1957–1963
  53. MacLennan SC, MacLennan AH, Ryan P. Colorectal cancer and oestrogen replacement therapy. A meta-analysis of epidemiological studies. Med J Aust. 1995;162(9):491–493
  54. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomised controlled trial. JAMA. 2002;288(3):321–333
  55. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomised controlled trial. JAMA. 2004;291(14):1701–1712
  56. Marnett LJ, DuBois RN. COX-2: a target for colon cancer prevention. Annu Rev Pharmacol Toxicol. 2002;42:55–80
  57. Shureiqi I, Chen D, Lotan R, et al. 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res. 2000;60(24):6846–6850
  58. Giovannucci e, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med. 1995;333(10):609–614
  59. Gann PH, Manson JE, Glynn RJ, et al. Low-dose aspirin and incidence of colorectal tumours in a randomised trial. J Natl Cancer Inst. 1993;85(15):1220–1224
  60. Sandler RS, Halabi S, Baron JA, et al. A randomised trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003;348(10):883–890
  61. Benamouzig R, Deyra J, Martin A, et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology. 2003;125(2):328–336
  62. Phillips RK, Wallace MH, Lynch PM, et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut. 2002;50(6):857–860
  63. Fiorucci S, Santucci L, Gresele P, et al. Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology. 2003;124(3):600–607
  64. Williams JL, Nath N, Chen J, et al. Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell factor signaling, nuclear factor-kappaB, and NO synthase 2 inhibition: implications for chemoprevention. Cancer Res. 2003;63(22):7613–7618
  65. Fiorucci S, Santucci L, Wallace JL, et al. Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. Proc Natl Acad Sci USA. 2003;100(19):10937–10941
  66. Cryer B, Kimmey MB. Gastrointestinal side effects of nonsteroidal anti-inflammatory drugs. Am J Med. 1998;105(1B):20S–30S
  67. Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA. 1999;96(13):7563–7568
  68. Hawkey CJ. COX-2 inhibitors. Lancet. 1999;353(9149):307–314
  69. Ntais C, Polycarpou A, Tsatsoulis A. Molecular epidemiology of prostate cancer: androgens and polymorphisms in androgen-related genes. Eur J Endocrinol. 2003;149(6):469–477
  70. Makridakis NM, di Salle E, Reichardt JK. Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II. Pharmacogenetics. 2000;10(5):407–413
  71. Andriole G, Bostwick D, Brawley O, et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol. 2004;172(4 Pt 1):1314–1317
  72. Sudbø J, Lippman SM, Lee JJ, et al. The influence of resection and aneuploidy on mortality in oral leukoplakia. N Engl J Med. 2004;350(14):1405–1413
  73. Mao L. Can molecular assessment improve classification of head and neck premalignancy?. Clin Cancer Res. 2000;6(2):321–322
  74. Sudbø J, Kildal W, Risberg B, et al. DNA content as a prognostic marker in patients with oral leukoplakia. N Engl J Med. 2001;344(17):1270–1278
  75. Hong WK, Endicott J, Itri LM, et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med. 1986;315(24):1501–1505
  76. Lotan R, Xu XC, Lippman SM, et al. Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med. 1995;332(21):1405–1410
  77. Chiesa F, Tradati N, Grigolato R, et al. Randomised trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: long-term results. Int J Cancer. 2005;115(4):625–629
  78. Dannenberg AJ, Lippman SM, Mann JR, et al. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol. 2005;23(2):254–266
  79. Sudbo J, Samuelsson R, Risberg B, et al. Risk markers of oral cancer in clinically normal mucosa as an aid in smoking cessation counseling. J Clin Oncol. 2005;23(9):1927–1933
  80. Beta Carotene Cancer Prevention Study Group The Alpha-Tocopherol. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994, 330 (15), 1029–35.
  81. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996;334(18):1150–1155
  82. Pastorino U, Infante M, Maioli M, et al. Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol. 1993;11(7):1216–1222
  83. van Zandwijk. Proc. ASCO 1999 [Abstract no. 18].
  84. Lee JS, Lippman SM, Benner SE, et al. Randomised placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. J Clin Oncol. 1994;12(5):937–945
  85. Lam S, leRiche JC, McWilliams A, Macaulay C, et al. A randomised phase IIb trial of pulmicort turbuhaler (budesonide) in people with dysplasia of the bronchial epithelium. Clin Cancer Res. 2004;10(19):6502–6511

PII: S0959-8049(05)00513-7

doi: 10.1016/j.ejca.2005.06.007

European Journal of Cancer
Volume 41, Issue 13 , Pages 1833-1841 , September 2005

Article Tools